Du veidai - Company finances
|
EUR
|
2021
From: 2021-10-22
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|
|
Financial data
|
|||||
| Sales revenue | 2,091 | 15,010 | 30,202 | 20,717 | 69,422 |
| Profit before tax | -253 | 1,181 | 2,393 | -2,143 | 13,354 |
| Net profit | -253 | 1,098 | 2,206 | -2,143 | 12,600 |
| Equity | -243 | 854 | 3,060 | 918 | 13,969 |
| Liabilities | - | 1,718 | 751 | 870 | 3,439 |
| Non-current assets | 0 | 0 | 0 | 0 | 0 |
| Current assets | 2,896 | 2,572 | 3,811 | 1,788 | 17,408 |
| Total assets | 2,896 | 2,572 | 3,811 | 1,788 | 17,408 |
|
Taxes paid
|
|||||
| STI taxes | - | - | 1,442 | 1,894 | 6,933 |
|
Financial indicators
|
|||||
| Revenue change y/y | - | +617.8% | +101.2% | -31.4% | +235.1% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -8.7% | 42.7% | 57.9% | -119.9% | 72.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | 128.6% | 72.1% | -233.4% | 90.2% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -12.1% | 7.3% | 7.3% | -10.3% | 18.1% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -12.1% | 7.9% | 7.9% | -10.3% | 19.2% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | 2.0 | 0.2 | 0.9 | 0.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Du veidai - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2025-11-01 | 2025-11-30 | 72.45 |
| 2025-10-01 | 2025-10-31 | 217.35 |
| 2025-09-02 | 2025-09-30 | 144.90 |
| 2025-08-01 | 2025-09-01 | 72.45 |
| 2025-05-04 | 2025-06-30 | 72.45 |
| 2025-04-01 | 2025-04-30 | 217.35 |
| 2025-03-04 | 2025-03-31 | 144.90 |
| 2025-03-03 | 2025-03-03 | 72.45 |
| 2025-03-01 | 2025-03-02 | 144.90 |
| 2025-02-01 | 2025-02-28 | 72.45 |
| 2025-01-16 | 2025-01-31 | 90.44 |
| 2025-01-02 | 2025-01-15 | 193.50 |
| 2024-12-03 | 2024-12-31 | 129.00 |
| 2024-11-04 | 2024-12-02 | 64.50 |
| 2024-10-01 | 2024-10-31 | 258.00 |
| 2024-09-03 | 2024-09-30 | 193.50 |
| 2024-08-01 | 2024-09-02 | 129.00 |
| 2024-07-02 | 2024-07-31 | 64.50 |
| 2024-06-03 | 2024-06-30 | 64.50 |
| 2024-05-02 | 2024-05-31 | 64.50 |
| 2024-04-03 | 2024-04-30 | 64.50 |
| 2024-03-01 | 2024-03-31 | 64.50 |
| 2023-03-01 | 2023-03-31 | 58.63 |
Du veidai - VMI tax arrears
As of 2026-09-02, the amount of overdue STI tax debt of the company Du veidai is: 0 €
| From | To | Overdue, € |
|---|---|---|
| 2026-09-01 | 2026-09-02 | 0.29 |
| 2025-10-18 | 2025-10-19 | 18.0 |
| 2025-04-28 | 2025-06-07 | 7.0 |
| 2025-03-28 | 2025-04-23 | 7.0 |
| 2025-02-09 | 2025-02-10 | 7.0 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Du veidai, MB (code 305921584) is a Small partnership engaged in retail sale of pharmaceutical products. In the latest financial year 2025, the company generated revenue of €69.4K and net profit of €12.6K, corresponding to a profit margin of 18.1%. Performance improved strongly from 2024, when revenue was €20.7K and the company recorded a net loss of €2.1K, after a profitable 2023 with revenue of €30.2K and net profit of €2.2K. Over the two-year period, revenue increased by 129.9%, and year on year growth in 2025 was 235.1%. The balance sheet strengthened materially in 2025, with total assets of €17.4K, equity of €14.0K and liabilities of €3.4K. Equity represented 80.2% of assets, while debt to equity stood at 0.25. Profitability ratios were high in 2025, with return on equity of 90.2% and return on assets of 72.4%, supported by an asset turnover of 3.99x. The company’s financial profile therefore shows a clear recovery and a much stronger operating result in 2025.